position of clinical intervention research in the ... - knaw
TRANSCRIPT
Position of clinical intervention research in the Netherlands and recent trends
Huibert A.P. Pols, MD, PhDRikard Juttmann, MD, PhD
Erasmus University Medical Center Rotterdam
Introduction
Publication output- Quantity
- Quality
- Focus
Comparison with other countries General trends SWOT analysis Challenges
Number of publications on clinical trialsin the Netherlands
NL
0
100
200
300
400
500
600
700
2005 2006 2007 2008 2009
NL
Number of publications on clinical trials per university medical center
0
20
40
60
80
100
120
140
160
180
2005 2006 2007 2008 2009
12345678
Types of clinical research within top 100 best cited articles (2000-2008)
Drug trials (33)
Other clinical trials (17)
Guidelines/ decision making (13)
Explorative /association studies (7)
Others, including biomedical and meta-analyses (30)
100 highest cited publications within Clinical Medicine per research field
0
5
10
15
20
25
30
35
Onc/Hem Cardvasc IntM/End Infect Others
Field citation score Dutch universities per research field
0
0,5
1
1,5
2
2,5
3
3,5
Med Cardio Onco Neuro Hema Endo Surg Rad
Average number of citations per publication specifically on clinical
trials per university (NL)
02468
1012141618
2 1 8 6 4 3 7 5
2005/9
2005/9
Number of publications on clinical trials as percentage of world output
05
101520253035404550
2005 2006 2007 2008 2009
USA
England
Germany
France
Netherlands
Sw itzerland
Sw eden
Belgium
Output of publications on clinical trials per 1 million inhabitants
0
10
20
30
40
50
60
2005 2006 2007 2008 2009
Sw itzerland
Netherlands
Sw eden
Belgium
England
Germany
USA
France
World
Output of publications on clinical trials per 1 trillion (1012) US dollars BNI
0100200300400500600700800900
1000
2005 2006 2007 2008 2009
SwitNlSweBeUSAGerFr
Top European institutions in clinical medicineTimes Higher Education 21 May 2009
Data provided by Thomson Reuters’ Essential Science Indicators database, 1 January 1998-31 December 2008
Rank in Europe
1
2
3
4
5
6
7
8
9
10
University or Institute
Erasmus University Rotterdam
University of Cambridge
University of Oxford
University of Glasgow
University of Helsinki
Imperial College London
University of Amsterdam
Karolinska Institute
Humboldt University of Berlin
Leiden University
Papers
7,108
4,795
6,706
4,908
10,169
7,550
8,123
12,787
6,097
8,150
Citations
166,015
107,088
149,545
104,245
206,196
145,914
150,269
236,174
112,420
149,851
Citations/Paper
23.36
22.33
22.30
21.24
20.28
19.33
18.50
18.47
18.44
18.39
TOP EUROPEAN INSTITUTIONS IN CLINICAL MEDICINE
Times Higher Education
A B C D E F A B C D E F
1 20 Rotterdam 7108 166015 23,36 11 68 London (Univ) 16761 302182 18,03
2 25 Cambridge 4795 107088 22,33 12 77 Uppsala 6327 105962 16,75
3 26 Oxford 6706 149545 22,30 13 79 Milan 8722 145331 16,66
4 31 Glasgow 4908 104245 21,24 14 80 Utrecht 8416 137602 16,35
5 40 Helsinki 10169 206169 20,28 15 81 Aarhus 6340 103629 16,35
6 50 London (Imp) 7550 145914 19,33 16 82 Vienna 8579 140063 16,33
7 59 Amsterdam 8123 150269 18,50 17 84 London (Kings) 8359 136382 16,32
8 60 Karolinska 12787 236174 18,47 18 85 Maastricht 6274 100910 16,15
9 61 Berlin 6097 112420 18,44 19 88 Zurich 8638 137050 15,87
10 62 Leiden 8150 149851 18,39 20 89 Lund 8041 127533 15,86
A = Rank in Europe, B = Rank in the World, C = University, D = n Papers, E = n Citations, F = Citations per Paper
Data provided by Thomson Reuters essential Science Indicators database, 1 January 1998 – 31 December 2008
Number of universities in top 20 European institutions in clinical
medicine per country
UK 6
Netherlands 5
Sweden 3
Finland 1
Germany 1
Italy 1
Denmark 1
Austria 1
Switzerland 1
Average number of citations per publication on clinical trials per
country
0,00
5,00
10,00
15,00
20,00
Be Switz Fr Sw NL Eng USA Ger
2005/9
2005/9
Investigator initiated research compared with industry initiated research
(trends in Erasmus MC)
0
50
100
150
200
250
300
350
2004 2005 2006 2007 2008
Investigator-initiated Industrie geïnitieerd
Consequences of shift from industry to investigator initiated research
In industry initiated (drug) studies, trial vigilance is usually well organized by the industry partner
- Monitoring
- Data Safety Monitoring Board (DSMB)
In investigator initiated research, usually the UMC is responsible for the execution of these tasks
If investigator initiated clinical research increases, UMC’s will become more vulnerable, because of limited possibilities with regard to trial vigilance.
Other developments in Clinical Research
External development Effect on clinical research output
TI Pharma, CTMM Limited increase
Priority medicines for children and the elderly Increase
Industry initiated research Decrease
Personalized medicine (mostly investigator initiated)
Probably increase
Orphan drugs (ZONMW, EU) Increase
“Parelsnoer”- initiative Increase
Comments from the industry: Matches between Academia and Medical Life
Science Industry
Research culture Excellent scientific knowlegde and facilities Many key opinion leaders Clinical data quality Many bottom-up initiaties Logistic infrastructure
Comments from the industry: Mismatches between Academia and Medical Life
Science Industry
Regulatory and legislative measures Ethical approval timelines Local feasibility Small patient populations Clinical trial performance Cost development Attitude towards clinical research Organisational innovations in academic centres Cooperation between reachers
Strength• Strong clinical research tradition• Relatively high and still growing output • Prominent position in Europe
SWOT Clinical Research in The Netherlands(1)
Weakness• Funding research (children/elderly)• Suboptimal impact in relation to comparable countries• Suboptimal match with industry
Threats• Administrative load as result of legislation• Growing clinical work load• Limited clinical research funding
Opportunities• Large, compact, accessible population• Possibilities to improve (ICT) infrastructure• Investment in inter-academic cooperation
SWOT Clinical Research in The Netherlands(2)
What are our Challenges?
Publications: quality before quantity!
Coping with demands resulting from legislation- training young researchers (BROK)- further development of trial monitoring systems - Data Safety Monitoring Boards
Optimize (ICT) infrastructure- trial/data management software- data storage facilities- computer power: grid applications
Closer cooperation between UMC’s
Investment in networks, including government, industry, academia